Ovarian Cancer Treatment Market Size, Share and Growth, Regional Analysis and Forecast – 2023
- OI-15 |
- Published date: Oct, 2018 |
- Oncology/Hematology |
- Pages
Introduction:
Ovarian Cancer is a disease of cells—the building blocks that form tissue in the body. Ovarian Cancer frequently occurs for strange reasons. But, about 15 out of 100 Ovarian Cancers are due to changes in genes that are passed down from a parent to a child. In addition, inside all cells are coded instructions for making new cells and controlling how cells behave. These coded instructions are called genes. Abnormal changes in genes can turn normal ovarian cells into cancer cells. According to NCBI, Ovarian cancer (OC) accounts for an estimated 239,000 new cases and 152,000 deaths worldwide annually and there were nearly 300,000 new cases in 2018.
Market Overview:
The global Ovarian Cancer Treatment market was valued at $ XX Mn in 2018 and is forecast to grow at a XX% CAGR between 2018 and 2026, resulting in 2026 global sales of $ XX. The market is driven by rising government funding and raise in an older woman population. However, patient expiry of the key patented drugs like paraplatin, taxol and gemzar are restraining the market growth. Moreover, growing health care awareness is providing ample opportunities for the market. Ovarian Cancer Treatment depending on the type of cancer, epithelial ovarian tumor segment is expected to account for the largest share of the Ovarian Cancer Treatment market due to 90 out of 100 ovarian cancers are epithelial ovarian cancer. Because it is the most common type, it is often simply referred to as Ovarian Cancer.
Key Developments:
- On May 28, 2019: Corcept Therapeutics has Presented Data from Phase 1/2 Trial of Relacorilant Plus Nab-Paclitaxel in Patients with Solid Tumors at the American Society of Clinical Oncology Annual Meeting
- On Apr 29, 2019; Lynparza has received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency for the treatment of germline BRCA-mutated HER2-negative metastatic ovarian cancer
The Global Ovarian Cancer Treatment market is segmented on the basis of drug class, type of cancer, distribution channel, end-user, and region.
- Based on Drug Class: Chemotherapeutic Agents, Targeted Therapy Drugs, Immune System Modulators and Hormones
- Based on Types: Epithelial Ovarian Tumor, Ovarian Germ Cell Tumor, Ovarian Stomatal Tumor, and Primary Peritoneal Carcinoma
- Based on Distribution Channel: Hospital Pharmacies, Retail Pharmacies, and Others
- Based on Region: North America, Asia-Pacific, Europe, and LAMEA. Among that North America held the largest share of the market. due to the rising number of the aging population. According to the American cancer society, in the U.S. about 22,440 women will receive a new diagnosis of ovarian cancer and about 14,080 women will die from ovarian cancer in 2017.
The key players of the Global Ovarian Cancer Treatment market are Hoffmann-La Roche AG, Johnson & Johnson, AstraZeneca, Clovis Oncology, GlaxoSmithKline plc, Boehringer Ingelheim GmbH and, Others.
Report Description:
The report includes in-depth company profiles of key players in the Global Ovarian Cancer Treatment Market. The company profile includes key information on the overview, financial highlights, product portfolio, business strategies, and key recent developments
The report highlights information on emerging companies with potentially disruptive technologies and new market entrants
Scope:
- Provides detailed analysis of the market structure along with forecast of the various segments and sub-segments of the Global Ovarian Cancer Treatment Market
- Provides a comparative analysis of key marketed and pipeline products
- Provides key information on players involved in the Global Ovarian Cancer Treatment Market
- Provides a complete overview of market segments and the regional outlook of Global Ovarian Cancer Treatment Market
- Provides in-depth coverage of key news related to Global Ovarian Cancer Treatment Market, including major mergers and acquisitions and product development updates such as clinical trial progression updates and regulatory updates
-
Data Collation (Primary & Secondary)
-
In-house Estimation (Based on proprietary databases and Models)
-
Market Triangulation
-
Forecasting
-
Market-related information is assembled from both primary and secondary sources.
-
Primary sources involved participants from all global stakeholders such as experts from several related industries and suppliers that have been interviewed to obtain and verify critical information as well as to assess prospects of the market. The participants included are CXOs, VPs, and managers. Plus, our in-house industry experts having decades of industry experience contribute their consulting and advisory services.
-
Secondary sources include public sources such as regulatory frameworks, government IT spending, government demographic indicators, industry association statistics, and company publications annual reports press releases along with paid sources such as Factiva, OneSource, Bloomberg among others.
-
Top-down and bottom-up approaches: The overall market size was used in the top-down approach to estimate the sizes of other individual submarkets (mentioned in the market segmentation by product, type of manufacturing, and disease) through percentage splits from secondary and primary research. The bottom-up approach was also implemented (wherever applicable) for data extracted from secondary research to validate the market segment revenues obtained.
